DOCSLIB.ORG

ISBT Science Series

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Science Series INTRODUCTION TO BLOOD TRANSFUSION: FROM DONOR TO RECIPIENT rstar @pikisupe Join the conversation on social media with the hashtag #IntrotoBloodTransfusion ISBT Science Series Volume 15 Supplement 1 December 2020 Special issue: Introduction to Blood Transfusion: From Donor to Recipient CONTENTS Volume 15, Number S1, December 2020 Special issue: Introduction to Blood Transfusion: From Donor to Recipient List of contributors………………………………………………………………………….. ............................................................................................. 1 First Edition • Introduction .......................................................................................................................................................................................... 3 Second Edition • Introduction .......................................................................................................................................................................................... 4 • Preface ................................................................................................................................................................................................... 5 Abbreviations ........................................................................................................................................................................................... 6 Glossary ....................................................................................................................................................................................... 8 Section 1 - Haematology ........................................................................................................................................................................ 46 Section 2 - Immunology ......................................................................................................................................................................... 54 Section 3 - Antigen-antibody reactions ............................................................................................................................................... 68 Section 4 - Principles of laboratory techniques ................................................................................................................................... 81 Section 5 - Genetics ...............................................................................................................................................................................112 Section 6 - Blood group systems ..........................................................................................................................................................123 Section 7 - Haemolytic diseases ........................................................................................................................................................... 151 Section 8 - Blood donors ......................................................................................................................................................................167 Section 9 - Blood collection .................................................................................................................................................................178 Section 10 - Donation testing and transfusion transmissible diseases ............................................................................................192 Section 11 - Blood processing and components ................................................................................................................................ 207 Section 12 - Blood storage and transportation ..................................................................................................................................232 Section 13 - Compatibility testing .......................................................................................................................................................255 Section 14 – Transfusion risks and haemovigilance .........................................................................................................................277 Section 15 - Safety, health and the environment ...............................................................................................................................292 Section 16 - Quality ..............................................................................................................................................................................300 Section 17 - Equipment and materials management ........................................................................................................................ 312 Section 18 - Indications for transfusion of blood components ........................................................................................................320 References ................................................................................................................................................................................ 331 ISBT Science Series (2020) 15, 1–2 © 2020 The Author. Journal Compilation © 2020 Blackwell Publishing Ltd. LIST OF CONTRIBUTORS ISBT Science Series DOI: 10.1111/voxs.12609 Editors of current edition Sanjay Gandhi Postgraduate Institute of Medical Sciences Beryl Cynthia Armstrong Luckow, Uttar Pradesh, India Botrivier West Cape, South Africa [email protected] [email protected] Gwen Clarke Robert Wilkinson Canadian Blood Services Knysna, Western Province, South Africa Edmonton, Alberta, Canada [email protected] [email protected] Mindy Goldman Masja de Haas, MD PhD Canadian Blood Services Sanquin Diagnostic Services Ottawa, Ontario, Canada Amsterdam, the Netherlands [email protected] [email protected] Mindy Goldman Reviewers of individual section(s) Canadian Blood Services Ottawa, Ontario, Canada Arwa Z. Al-Riyami. BSc., MD, FRCPC [email protected] Sultan Qaboos University Hospital Muscat, Sultanate of Oman Carlos Alberto Gonzalez, MD [email protected] Hospital de Infecciosas F. J. Muniz~ Buenos Aires, Argentina Awale Rupali Bhalchandra, MBBS,MD [email protected] Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rahul Katharia, MD Luckow, Uttar Pradesh, India Sanjay Gandhi Postgraduate Institute [email protected] of Medical Sciences Luckow, Uttar Pradesh, India Maha Badawi [email protected] King Abdulaziz University Jeddah, Saudi Arabia Dheeraj Khetan, MD [email protected] Sanjay Gandhi Postgraduate Institute of Medical Sciences Linley Bielby Luckow, Uttar Pradesh, India The Australian Red Cross Blood Service [email protected] Melbourne, Victoria, Australia [email protected] So-Yong Kwon, MD, PhD Korean Red Cross Blood Services Melanie Bodnar, MD Wonju, Gangwon-do, Korea Canadian Blood Services [email protected] Edmonton, Alberta, Canada [email protected] Edmond Lee Macao Blood Transfusion Service Lesley Bust, B Pharm Macao, China Consultant to Africa Society for Blood Transfusion [email protected] Cape Town, Western Cape, South Africa [email protected] Miquel Lozano, MD, PhD University Clinic Hospital/University of Barcelona Lilian Castilho, PhD Barcelona, Catalonia, Spain Hemocentro-Unicamp [email protected] Campinas, S~ao Paulo, Brazil [email protected] Malcolm Needs, CSci, FIBMS FBBTS Somerset, England Judith F. Chapman [email protected] Cheltenham, UK [email protected] Veera Sekaran Nadarajan Universiti Tunku Abdul Rahman Rajendra Chaudhary, MD 1 2 Bandar Sungai Long, Malaysia Contributors of new section [email protected] Shamee Shastry, MBBS, MD Miquel Lozano, MD, PhD Kasturba Medical College, Manipal University Clinic Hospital/University of Barcelona Manipal. Karnataka, India Barcelona, Catalonia, Spain [email protected] [email protected] Neil Waters Maha Badawi Monash University King Abdulaziz University Melbourne, Victoria, Australia Jeddah, Saudi Arabia [email protected] [email protected] Jennifer L. White International Society of Blood Transfusion Amsterdam, North-Holland, The Netherlands [email protected] © 2020 The Author. Journal Compilation © 2020 Blackwell Publishing Ltd. ISBT Science Series (2020) 15, 1–2 ISBT Science Series (2020) 15,3 © 2020 The Author. Journal Compilation © 2020 Blackwell Publishing Ltd. INTRODUCTION ISBT Science Series DOI: 10.1111/voxs.12610 First Edition Introduction to Blood Transfusion Technology In 1989, following several years of being national exam- reactions, causes of false results, genetics, blood group and iner for blood transfusion technology in South Africa, I HLA systems, blood donation and storage, blood components, wrote a book that was updated in 1992: Introduction to safety in the laboratory, quality control and assurance, profi- Blood Transfusion Technology. The aim was to provide ciency testing, donor grouping and the detection of viral written information as simply as possible, so that students markers, crossmatching, transfusion reactions, blood trans- who found themselves without adequate training and fusion regulations, haemolytic disease of the newborn, ante- support were able to gain knowledge for themselves. The natal and postnatal testing, haemolytic anaemias, laboratory book was privately printed and distributed in South glassware and equipment and sterilization. Africa for many years. Some copies also found their way This publication is not an updated edition of the original to other parts
Recommended publications
  • Transfusion Service Introduction Blood/Blood Products Requests and Turnaround Time Expectations

    Transfusion Service Introduction Blood/Blood Products Requests and Turnaround Time Expectations

    Transfusion Service Introduction All blood products and blood components are supplied to UnityPoint Health-Meriter Hospital by the American Red Cross Blood Services. Pathology consultation is available regarding blood and/or components and dosages. ABO and Rho(D)—specific type is used whenever possible for leuko-poor packed cell transfusions. ABO-compatible blood is used for all plasma and platelet components whenever possible. For any orders involving HLA-matched components, the patient must have been HLA typed (sent to the American Red Cross) a minimum of 48 hours prior to intended infusion of the component. HLA typing is only required once. Blood components that are thawed, pooled, washed, volume-reduced, or deglycerolized for a patient will be charged to the patient even if not transfused. The charge is done because these components may not be suitable for another patient. Examples include: Autologous or directed donations Pooled cryoprecipitate 4-hour expiration Thawed fresh frozen plasma 24-hour expiration Thawed cryoprecipitate 6-hour expiration Deglycerolized red cells 24-hour expiration Washed red cells 24-hour expiration All blood components must be completely infused within 4 hours of release from UnityPoint Health-Meriter Laboratories Blood Bank, or be infused within the expiration time. Refer to UnityPoint Health -Meriter’s Blood and Blood Products Transfusion Policy #123 for additional information located on MyMeriter. Blood/Blood Products Requests and Turnaround Time Expectations Requests from UnityPoint Health-Meriter Hospital are entered in the hospital computer system and print in the UnityPoint Health- Meriter Laboratories Blood Bank. For the comfort of the patient, it is important to coordinate collection for other tests with Blood Bank specimens.
  • Transfusion Problems in Hemolytic Anemias*

    Transfusion Problems in Hemolytic Anemias*

    Transfusion Problems in Hemolytic Anemias* ALI A. HOSSAIN! Department of Pathdlogy, Medical College of Virginia, Richmond 23219 All hemolytic anemias feature shortened red cell Extrinsic Mechanisms survival due to premature hemolysis of the cell. For the Those hemolytic anemias which are due to extrinsic purposes of this presentation, we may classify the factors may be classified, further, as non-immune or hemolytic anemias, most broadly, according to the immune. Non-immune mechanisms include a) drugs mechanisms leading to hemolysis. and chemicals (phenylhydrazine, naphthalene, lead, snake venoms); b) physical agents (heat); c) bacteria Intrinsic Mechanisms and parasites (hemolytic streptococci, Clostridium Hemolytic anemias due to intrinsically defective welchii, Bartonella, plasmodia); and d) acquired sen­ erythrocytes are essentially of three types. First are sitivity to penicillin, methylodopa, Keftin®, or fava those anemias in which the red cells are defective due plant as examples. Some of the agents in this. last to lack of an essential factor, eg, pernicious anemia group serve to lyse the cells, either through duect in relapse. The second type includes those in which action or by formation of antibodies. the red cells have an abnormal shape because of an These hemolytic anemias due to extrinsic factors inherited error in the chemical makeup of the hemo­ of the non-immune variety present no transfusion globin molecules; eg, sickle cells, elliptocytes, sphero­ problem for the Blood Bank. However, it ~~st b.e cytes, and the target
  • ST-002 ISBT 128 Standard Terminology for Medical Products of Human Origin

    ST-002 ISBT 128 Standard Terminology for Medical Products of Human Origin

    ISBT 128 STANDARD Standard Terminology for Medical Products of Human Origin For Use with Product Description Code Database Version 7.54 September 2021 Tracking Number ICCBBA ST-002 Published by: ICCBBA PO Box 11309, San Bernardino, CA 92423-1309 USA Standard Terminology for Medical Products of Human Origin v7.54 Editor Ryan Ruiz, BS Information Standards Specialist, ICCBBA Standards Committee Wayne Bolton, BAppSc, MAppSc Standards Committee, APTAG, TAG-IT Chair Paul Ashford, MSc, CEng, CSci ICCBBA Executive Director Debbie Barnett MBE, RGN, RM, BSc MBTAG Chair Suzanne Butch, MA, MT(ASCP)SBB ATAG Chair Jørgen Georgsen, MD Technical Expert Martin Hildebrandt, MD RMTAG Chair Jelena Holovati, PhD, MLT(CSMLS), MT(ASCP) NATTAG Chair Karen Moniz, MHA, MT(ASCP)SBB ICCBBA Technical Director Mario Muon, MD EMATAG Chair Diego Ponzin, MD EBTAG Chair Leigh Sims Poston, BS, MT(ASCP) Technical Expert Ineke Slaper-Cortenbach, PhD Technical Expert Zbigniew Szczepiorkowski, MD, PhD, FCAP CTCLAG Chair Kelly Tilleman, PhD, MSc ARTTAG Chair Izabela Uhrynowska-Tyszkiewicz, MD, PhD ETTAG, ITTAG Chair © 2021 ICCBBA, All Rights Reserved 1 www.isbt128.org Standard Terminology for Medical Products of Human Origin v7.54 COPYRIGHT, WARRANTY, AND LIABILITY NOTICE Copyright 2021. ISBT 128 is not in the public domain and is protected by law. Implementation of ISBT 128 requires the end-user to register with ICCBBA and to pay an annual license fee. License fees are established by the ICCBBA Board of Directors to cover the expenses of maintaining and extending ISBT 128, and making available current versions of documents and database tables. Any use of this document, or the accompanying database tables, by other than registered organizations, or facilities that have obtained their computer software from a registered and licensed developer, is strictly forbidden.
  • Unintentional Platelet Removal by Plasmapheresis

    Unintentional Platelet Removal by Plasmapheresis

    Journal of Clinical Apheresis 16:55–60 (2001) Unintentional Platelet Removal by Plasmapheresis Jedidiah J. Perdue,1 Linda K. Chandler,2 Sara K. Vesely,1 Deanna S. Duvall,2 Ronald O. Gilcher,2 James W. Smith,2 and James N. George1* 1Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 2Oklahoma Blood Institute, Oklahoma City, Oklahoma Therapeutic plasmapheresis may remove platelets as well as plasma. Unintentional platelet loss, if not recognized, may lead to inappropriate patient assessment and treatment. A patient with thrombotic thrombocytopenic purpura- hemolytic uremic syndrome (TTP-HUS) is reported in whom persistent thrombocytopenia was interpreted as continuing active disease; thrombocytopenia resolved only after plasma exchange treatments were stopped. This observation prompted a systematic study of platelet loss with plasmapheresis. Data are reported on platelet loss during 432 apheresis procedures in 71 patients with six disease categories using three different instruments. Com- paring the first procedure recorded for each patient, there was a significant difference among instrument types ,than with the COBE Spectra (1.6% (21 ס P<0.001); platelet loss was greater with the Fresenius AS 104 (17.5%, N) .With all procedures, platelet loss ranged from 0 to 71% .(24 ס or the Haemonetics LN9000 (2.6%, N (26 ס N Among disease categories, platelet loss was greater in patients with dysproteinemias who were treated for hyper- viscosity symptoms. Absolute platelet loss with the first recorded apheresis procedure, in the 34 patients who had a normal platelet count before the procedure, was also greater with the AS 104 (2.23 × 1011 platelets) than with the Spectra (0.29 × 1011 platelets) or the LN9000 (0.37 × 1011 platelets).
  • Hemolytic Disease of the Newborn

    Hemolytic Disease of the Newborn

    Intensive Care Nursery House Staff Manual Hemolytic Disease of the Newborn INTRODUCTION and DEFINITION: Hemolytic Disease of the Newborn (HDN), also known as erythroblastosis fetalis, isoimmunization, or blood group incompatibility, occurs when fetal red blood cells (RBCs), which possess an antigen that the mother lacks, cross the placenta into the maternal circulation, where they stimulate antibody production. The antibodies return to the fetal circulation and result in RBC destruction. DIFFERENTIAL DIAGNOSIS of hemolytic anemia in a newborn infant: -Isoimmunization -RBC enzyme disorders (e.g., G6PD, pyruvate kinase deficiency) -Hemoglobin synthesis disorders (e.g., alpha-thalassemias) -RBC membrane abnormalities (e.g., hereditary spherocytosis, elliptocytosis) -Hemangiomas (Kasabach Merritt syndrome) -Acquired conditions, such as sepsis, infections with TORCH or Parvovirus B19 (anemia due to RBC aplasia) and hemolysis secondary to drugs. ISOIMMUNIZATION A. Rh disease (Rh = Rhesus factor) (1) Genetics: Rh positive (+) denotes presence of D antigen. The number of antigenic sites on RBCs varies with genotype. Prevalence of genotype varies with the population. Rh negative (d/d) individuals comprise 15% of Caucasians, 5.5% of African Americans, and <1% of Asians. A sensitized Rh negative mother produces anti-Rh IgG antibodies that cross the placenta. Risk factors for antibody production include 2nd (or later) pregnancies*, maternal toxemia, paternal zygosity (D/D rather than D/d), feto-maternal compatibility in ABO system and antigen load. (2) Clinical presentation of HDN varies from mild jaundice and anemia to hydrops fetalis (with ascites, pleural and pericardial effusions). Because the placenta clears bilirubin, the chief risk to the fetus is anemia. Extramedullary hematopoiesis (due to anemia) results in hepatosplenomegaly.
  • Association Between ABO and Duffy Blood Types and Circulating Chemokines and Cytokines

    Association Between ABO and Duffy Blood Types and Circulating Chemokines and Cytokines

    Genes & Immunity (2021) 22:161–171 https://doi.org/10.1038/s41435-021-00137-5 ARTICLE Association between ABO and Duffy blood types and circulating chemokines and cytokines 1 2 3 4 5 6 Sarah C. Van Alsten ● John G. Aversa ● Loredana Santo ● M. Constanza Camargo ● Troy Kemp ● Jia Liu ● 4 7 8 Wen-Yi Huang ● Joshua Sampson ● Charles S. Rabkin Received: 11 February 2021 / Revised: 30 April 2021 / Accepted: 17 May 2021 / Published online: 8 June 2021 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021, corrected publication 2021 Abstract Blood group antigens are inherited traits that may play a role in immune and inflammatory processes. We investigated associations between blood groups and circulating inflammation-related molecules in 3537 non-Hispanic white participants selected from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Whole-genome scans were used to infer blood types for 12 common antigen systems based on well-characterized single-nucleotide polymorphisms. Serum levels of 96 biomarkers were measured on multiplex fluorescent bead-based panels. We estimated marker associations with blood type using weighted linear or logistic regression models adjusted for age, sex, smoking status, and principal components of p 1234567890();,: 1234567890();,: population substructure. Bonferroni correction was used to control for multiple comparisons, with two-sided values < 0.05 considered statistically significant. Among the 1152 associations tested, 10 were statistically significant. Duffy blood type was associated with levels of CXCL6/GCP2, CXCL5/ENA78, CCL11/EOTAXIN, CXCL1/GRO, CCL2/MCP1, CCL13/ MCP4, and CCL17/TARC, whereas ABO blood type was associated with levels of sVEGFR2, sVEGFR3, and sGP130.
  • Guidelines for the Blood Transfusion Services

    Guidelines for the Blood Transfusion Services

    Joint United Kingdom (UK) Blood Transfusion and Tissue PDF Generated JPAC Transplantation Services Professional Advisory Committee 26/09/2021 08:32 Guidelines for the Blood Transfusion Services Index http://www.transfusionguidelines.org/red-book/index Index Names of blood components are in bold type. Page numbers relating to tabulated information are in italics. ABO grouping anomalous 222–3, 224 antisera 188–96 of blood 222–3 of donations 216 fully automated 222 indication on dispatch note 68 indication on labels 316, 317–18 mismatched transplant testing 226 molecular genetics 231 in the presence of autoantibodies 224 quality control 216 acute coronary syndrome 56 additive solutions 135 advanced therapy medicinal product (ATMP) 293 adverse events/reactions EU directives 7, 8, 14 febrile transfusion reactions 249 haemolytic transfusion reactions (HTRs) 218 International Haemovigilance Network categories for 54–6 recording and reporting 21–2, 42, 51–2 serious/severe 14, 21, 56, 281 page 1 of 67 Guidelines for the Blood Transfusion Services / Index suspected bacterial contamination of blood components 176 tissue and organs 281 TRALI 234, 244, 248–9, 253, 254 transfusion reactions 176, 178, 218, 249 air embolism 56 air quality 61, 274 alarm systems 44, 144, 296 alert/action levels, processing facilities 175 allergic reactions 55, 56 alloadsorption techniques 223 alloantibodies in anomalous ABO grouping 222 detection in the presence of autoantibodies 224–5 alternative assay testing, definition 161 ambient temperature 61 amnion donation 266
  • Platelet-Rich Plasmapheresis: a Meta-Analysis of Clinical Outcomes and Costs

    Platelet-Rich Plasmapheresis: a Meta-Analysis of Clinical Outcomes and Costs

    THE jOURNAL OF EXTRA-CORPOREAL TECHNOLOGY Original Article Platelet-Rich Plasmapheresis: A Meta-Analysis of Clinical Outcomes and Costs Chris Brown Mahoney , PhD Industrial Relations Center, Carlson School of Management, University of Minnesota, Minneapolis, MN Keywords: platelet-rich plasmapheresis, sequestration, cardiopulmonary bypass, outcomes, economics, meta-analysis Presented at the American Society of Extra-Corporeal Technology 35th International Conference, April 3-6, 1997, Phoenix, Arizona ABSTRACT Platelet-rich plasmapheresis (PRP) just prior to cardiopulmonary bypass (CPB) surgery is used to improve post CPB hemostasis and to minimize the risks associated with exposure to allogeneic blood and its components. Meta-analysis examines evidence ofPRP's impact on clinical outcomes by integrating the results across published research studies. Data on clinical outcomes was collected from 20 pub­ lished studies. These outcomes, DRG payment rates, and current national average costs were used to examine the impact of PRP on costs. This study provides evidence that the use of PRP results in improved clinical outcomes when compared to the identical control groups not receiving PRP. These improved clinical out­ comes result in subsequent lower costs per patient in the PRP groups. All clinical outcomes analyzed were improved: blood product usage, length of stay, intensive care stay, time to extu­ bation, incidence of cardiovascular accident, and incidence of reoperation. The most striking differences occur in use of all blood products, particularly packed red blood cells. This study provides an example of how initial expenditure on technology used during CPB results in overall cost savings. Estimated cost savings range from $2,505.00 to $4,209.00.
  • Journal of Blood Group Serology and Molecular Genetics Volume 34, Number 1, 2018 CONTENTS

    Journal of Blood Group Serology and Molecular Genetics Volume 34, Number 1, 2018 CONTENTS

    Journal of Blood Group Serology and Molecular Genetics VOLUME 34, N UMBER 1, 2018 This issue of Immunohematology is supported by a contribution from Grifols Diagnostics Solutions, Inc. Dedicated to advancement and education in molecular and serologic immunohematology Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 34, Number 1, 2018 CONTENTS S EROLOGIC M ETHOD R EVIEW 1 Warm autoadsorption using ZZAP F.M. Tsimba-Chitsva, A. Caballero, and B. Svatora R EVIEW 4 Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, Friday, September 2, 2016, Dubai A brief overview of clinical significance of blood group antibodies M.J. Gandhi, D.M. Strong, B.I. Whitaker, and E. Petrisli C A S E R EPORT 7 Management of pregnancy sensitized with anti-Inb with monocyte monolayer assay and maternal blood donation R. Shree, K.K. Ma, L.S. Er and M. Delaney R EVIEW 11 Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, Friday, September 2, 2016, Dubai A review of in vitro methods to predict the clinical significance of red blood cell alloantibodies S.J. Nance S EROLOGIC M ETHOD R EVIEW 16 Recovery of autologous sickle cells by hypotonic wash E. Wilson, K. Kezeor, and M. Crosby TO THE E DITOR 19 The devil is in the details: retention of recipient group A type 5 years after a successful allogeneic bone marrow transplant from a group O donor L.L.W.
  • Apheresis Donation This Quick Reference Guide Will Help You Identify the Best Donation for Your Unique Blood Type

    Apheresis Donation This Quick Reference Guide Will Help You Identify the Best Donation for Your Unique Blood Type

    Apheresis Donation This quick reference guide will help you identify the best donation for your unique blood type. Donors now have the opportunity to make an apheresis (ay-fur-ee-sis) donation and donate just platelets, red cells, or plasma at blood drives. These individual components are vital for local patients in need. Platelets Control Bleeding Red Cells Deliver Oxygen Plasma transports blood cells & controls bleeding Donation Type Blood Types Requirements Donation Time A+, B+, O+ Over 75% of population has one of these blood types. Platelet Donation: Be healthy, weigh at least 114 lbs 2 hours cancer & surgery patients no aspirin for 48 hours Platelets only last five days after donation so the need is constant. O-, O+, A-, B- Special height, weight, Double Red: O-Negative is the 1 hour and hematocrit requirements. surgery, trauma patients, universal red cell donor. +25 min Please call us or see a staff member accident, & burn victims Only 17% of population has one of these negative blood types Plasma: AB+, AB- Trauma patients, burn Universal Plasma Donors 1 hour Be healthy, weigh at least 114 lbs victims, & patients with +30 min serious illness or injuries Only 4% of population How Apheresis works: Blood is drawn from the donor’s arm and the components are separated. Only the components being donated are collected while the remaining components are safely returned to the donor How to Schedule an Appointment: Please call 800-398-7888 or visit schedule.bloodworksnw.org. Walk-ins are also welcome at some blood drives, so be sure to ask our staff when you stop in.
  • Patient's Guide to Blood Transfusions

    Patient's Guide to Blood Transfusions

    Health Information For Patients and the Community A Patient’s Guide to Blood Transfusions Your doctor may order a blood transfusion as part of your therapy. This brochure will focus on frequently asked questions about blood products, transfusions, and the risks and benefits of the blood transfusion. PLEASE NOTE: This information is not intended to replace the medical advice of your doctor or health care provider and is intended for educational purposes only. Individual circumstances will affect your individual risks and benefits. Please discuss any questions or concerns with your doctor. What is a blood transfusion? A blood transfusion is donated blood given to patients with abnormal blood levels. The patient may have abnormal blood levels due to blood loss from trauma or surgery, or as a result of certain medical problems. The transfusion is done with one or more of the following parts of blood: red blood cells, platelets, plasma, or cryoprecipitate. What are the potential benefits of a blood transfusion? If your body does not have enough of one of the components of blood, you may develop serious life-threatening complications. • Red blood cells carry oxygen through your body to your heart and brain. Adequate oxygen is very important to maintain life. • Platelets and cryoprecipitate help to prevent or control bleeding. • Plasma replaces blood volume and also may help to prevent or control bleeding. How safe are blood transfusions? Blood donors are asked many questions about their health, behavior, and travel history in order to ensure that the blood supply is as safe as it can be. Only people who pass the survey are allowed to donate.
  • Guidelines for Transfusion and Patient Blood Management, and Discuss Relevant Transfusion Related Topics

    Guidelines for Transfusion and Patient Blood Management, and Discuss Relevant Transfusion Related Topics

    Guidelines for Transfusion and Community Transfusion Committee Patient Blood Management Community Transfusion Committee CHAIR: Aina Silenieks, M.D., [email protected] MEMBERS: A.Owusu-Ansah, M.D. S. Dunder, M.D. M. Furasek, M.D. D. Lester, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Juliana Cordero, Blood Bank Coordinator, CHI Health Nebraska Heart REPRESENTATIVES: Becky Croner, Laboratory Services Manager, CHI Health St. Elizabeth Mackenzie Gasper, Trauma Performance Improvement, Bryan Medical Center Kelly Gillaspie, Account Executive, Nebraska Community Blood Bank Mel Hanlon, Laboratory Specialist - Transfusion Medicine, Bryan Medical Center Kyle Kapple, Laboratory Quality Manager, Bryan Medical Center Lauren Kroeker, Nurse Manager, Bryan Medical Center Christina Nickel, Clinical Laboratory Director, Bryan Medical Center Rachael Saniuk, Anesthesia and Perfusion Manager, Bryan Medical Center Julie Smith, Perioperative & Anesthesia Services Director, Bryan Medical Center Elaine Thiel, Clinical Quality Improvement/Trans. Safety Officer, Bryan Med Center Kelley Thiemann, Blood Bank Lead Technologist, CHI Health St. Elizabeth Cheryl Warholoski, Director, Nebraska Operations, Nebraska Community Blood Bank Jackie Wright, Trauma Program Manager, Bryan Medical Center CONSULTANTS: Jed Gorlin, M.D., Innovative Blood Resources [email protected] Michael Kafka, M.D., LifeServe Blood Center [email protected] Alex Smith, D.O., LifeServe Blood Center [email protected] Nancy Van Buren, M.D., Innovative